DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology

被引:3
|
作者
Grypari, Ioanna-Maria [1 ]
Tzelepi, Vasiliki [2 ]
Gyftopoulos, Kostis [3 ]
机构
[1] Natl Kapodistrian Univ Athens, Aretaie Univ Hosp, Cytol Dept, Athens 11528, Greece
[2] Univ Patras, Sch Med, Dept Pathol, Patras 26504, Greece
[3] Univ Patras, Sch Med, Dept Anat, Patras 26504, Greece
关键词
prostate cancer; DNA damage repair; homologous recombination deficiency; mismatch repair pathway; biomarkers; MICROSATELLITE INSTABILITY; INTRADUCTAL CARCINOMA; PROMOTER HYPERMETHYLATION; RADICAL PROSTATECTOMY; PARP; INHIBITORS; THERAPIES; GERMLINE; RISK; PD-1;
D O I
10.3390/ijms241411418
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) has a distinct molecular signature, including characteristic chromosomal translocations, gene deletions and defective DNA damage repair mechanisms. One crucial pathway involved is homologous recombination deficiency (HRD) and it is found in almost 20% of metastatic castrate-resistant PCa (mCRPC). Inherited/germline mutations are associated with a hereditary predisposition to early PCa development and aggressive behavior. BRCA2, ATM and CHECK2 are the most frequently HRD-mutated genes. BRCA2-mutated tumors have unfavorable clinical and pathological characteristics, such as intraductal carcinoma. PARP inhibitors, due to the induction of synthetic lethality, have been therapeutically approved for mCRPC with HRD alterations. Mutations are detected in metastatic tissue, while a liquid biopsy is utilized during follow-up, recognizing acquired resistance mechanisms. The mismatch repair (MMR) pathway is another DNA repair mechanism implicated in carcinogenesis, although only 5% of metastatic PCa is affected. It is associated with aggressive disease. PD-1 inhibitors have been used in MMR-deficient tumors; thus, the MMR status should be tested in all metastatic PCa cases. A surrogate marker of defective DNA repair mechanisms is the tumor mutational burden. PDL-1 expression and intratumoral lymphocytes have ambivalent predictive value. Few experimental molecules have been so far proposed as potential biomarkers. Future research may further elucidate the role of DNA damage pathways in PCa, revealing new therapeutic targets and predictive biomarkers.
引用
收藏
页数:26
相关论文
共 50 条
  • [21] Double-strand DNA break repair: molecular mechanisms and therapeutic targets
    Tan, Jinpeng
    Sun, Xingyao
    Zhao, Hongling
    Guan, Hua
    Gao, Shanshan
    Zhou, Ping-Kun
    MEDCOMM, 2023, 4 (05):
  • [22] Eph receptors and their ligands: Promising molecular biomarkers and therapeutic targets in prostate cancer
    Lisle, Jessica E.
    Mertens-Walker, Inga
    Rutkowski, Raphael
    Herington, Adrian C.
    Stephenson, Sally-Anne
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1835 (02): : 243 - 257
  • [23] Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer's Disease: A Systematic Review
    Premkumar, T.
    Lulu, S. Sajitha
    NEUROCHEMICAL JOURNAL, 2022, 16 (04) : 443 - 455
  • [24] Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer’s Disease: A Systematic Review
    T. Premkumar
    S. Sajitha Lulu
    Neurochemical Journal, 2022, 16 : 443 - 455
  • [25] DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies
    Mirza-Aghazadeh-Attari, Mohammad
    Ostadian, Caspian
    Saei, Amir Ata
    Mihanfar, Ainaz
    Darband, Saber Ghazizadeh
    Sadighparvar, Shirin
    Kaviani, Mojtaba
    Kafil, Hossein Samadi
    Yousefi, Bahman
    Majidinia, Maryam
    DNA REPAIR, 2019, 80 : 59 - 84
  • [26] Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme
    Mittal, Pooja
    Sinha, Rajesh
    Kumar, Amit
    Singh, Pooja
    Ngasainao, Moses Rinchui
    Singh, Archana
    Singh, Indrakant K.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (05) : 390 - 408
  • [27] Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
    Mirzaei, Sepideh
    Paskeh, Mahshid Deldar Abad
    Okina, Elena
    Gholami, Mohammad Hossein
    Hushmandi, Kiavash
    Hashemi, Mehrdad
    Kalu, Azuma
    Zarrabi, Ali
    Nabavi, Noushin
    Rabiee, Navid
    Sharifi, Esmaeel
    Karimi-Maleh, Hassan
    Ashrafizadeh, Milad
    Kumar, Alan Prem
    Wang, Yuzhuo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [28] Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
    Sepideh Mirzaei
    Mahshid Deldar Abad Paskeh
    Elena Okina
    Mohammad Hossein Gholami
    Kiavash Hushmandi
    Mehrdad Hashemi
    Azuma Kalu
    Ali Zarrabi
    Noushin Nabavi
    Navid Rabiee
    Esmaeel Sharifi
    Hassan Karimi-Maleh
    Milad Ashrafizadeh
    Alan Prem Kumar
    Yuzhuo Wang
    Journal of Experimental & Clinical Cancer Research, 41
  • [29] Molecular testing of DNA damage response pathways in prostate cancer patients
    Patel, Lalit
    Pritchard, Colin C.
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (03) : 224 - 230
  • [30] The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
    Burgess, Joshua T.
    Rose, Maddison
    Boucher, Didier
    Plowman, Jennifer
    Molloy, Christopher
    Fisher, Mark
    O'Leary, Connor
    Richard, Derek J.
    O'Byrne, Kenneth J.
    Bolderson, Emma
    FRONTIERS IN ONCOLOGY, 2020, 10